193 related articles for article (PubMed ID: 1320533)
1. Mechanisms of neuronal loss in Parkinson's disease: a neuroanatomical-biochemical perspective.
Hornykiewicz O
Clin Neurol Neurosurg; 1992; 94 Suppl():S9-11. PubMed ID: 1320533
[TBL] [Abstract][Full Text] [Related]
2. Does oxidative stress participate in nerve cell death in Parkinson's disease?
Hirsch EC
Eur Neurol; 1993; 33 Suppl 1():52-9. PubMed ID: 8375433
[TBL] [Abstract][Full Text] [Related]
3. Early-stage loss of dopamine uptake-site binding in MPTP-treated monkeys.
Graybiel AM; Moratalla R; Quinn B; DeLanney LE; Irwin I; Langston JW
Adv Neurol; 1993; 60():34-9. PubMed ID: 8420148
[No Abstract] [Full Text] [Related]
4. [Striato-nigral degeneration (SND): a multisystem atrophy?].
Bergmann M; Schmidtke K; Danek A; Gullotta F; Mehraein P
Schweiz Arch Neurol Psychiatr (1985); 1990; 141(5):389-405. PubMed ID: 1701267
[TBL] [Abstract][Full Text] [Related]
5. Nigral degeneration and striatal dopaminergic dysfunction in idiopathic and Parkin-linked Parkinson's disease.
Hu MT; Scherfler C; Khan NL; Hajnal JV; Lees AJ; Quinn N; Wood NW; Brooks DJ
Mov Disord; 2006 Mar; 21(3):299-305. PubMed ID: 16211589
[TBL] [Abstract][Full Text] [Related]
6. MRI detects acute degeneration of the nigrostriatal dopamine system after MPTP exposure in hemiparkinsonian monkeys.
Miletich RS; Bankiewicz KS; Quarantelli M; Plunkett RJ; Frank J; Kopin IJ; Di Chiro G
Ann Neurol; 1994 Jun; 35(6):689-97. PubMed ID: 8210225
[TBL] [Abstract][Full Text] [Related]
7. Stable parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboons.
Hantraye P; Varastet M; Peschanski M; Riche D; Cesaro P; Willer JC; Maziere M
Neuroscience; 1993 Mar; 53(1):169-78. PubMed ID: 8469305
[TBL] [Abstract][Full Text] [Related]
8. Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease.
Mavridis M; Degryse AD; Lategan AJ; Marien MR; Colpaert FC
Neuroscience; 1991; 41(2-3):507-23. PubMed ID: 1870701
[TBL] [Abstract][Full Text] [Related]
9. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
Huot P; Lévesque M; Parent A
Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
[TBL] [Abstract][Full Text] [Related]
10. Clues to the mechanism underlying dopamine cell death in Parkinson's disease.
Jenner P
J Neurol Neurosurg Psychiatry; 1989 Jun; Suppl(Suppl):22-8. PubMed ID: 2666576
[TBL] [Abstract][Full Text] [Related]
11. Nigral degeneration in Parkinson's disease.
Rinne JO
Mov Disord; 1993; 8 Suppl 1():S31-5. PubMed ID: 8302305
[TBL] [Abstract][Full Text] [Related]
12. Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease.
Scherfler C; Esterhammer R; Nocker M; Mahlknecht P; Stockner H; Warwitz B; Spielberger S; Pinter B; Donnemiller E; Decristoforo C; Virgolini I; Schocke M; Poewe W; Seppi K
Brain; 2013 Oct; 136(Pt 10):3028-37. PubMed ID: 24014521
[TBL] [Abstract][Full Text] [Related]
13. Analysis of gene expression in Parkinson's disease: possible involvement of neurotrophic support and axon guidance in dopaminergic cell death.
Bossers K; Meerhoff G; Balesar R; van Dongen JW; Kruse CG; Swaab DF; Verhaagen J
Brain Pathol; 2009 Jan; 19(1):91-107. PubMed ID: 18462474
[TBL] [Abstract][Full Text] [Related]
14. Adaptive changes in the nigrostriatal pathway in response to increased 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration in the mouse.
Bezard E; Jaber M; Gonon F; Boireau A; Bloch B; Gross CE
Eur J Neurosci; 2000 Aug; 12(8):2892-900. PubMed ID: 10971632
[TBL] [Abstract][Full Text] [Related]
15. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey.
Pifl C; Schingnitz G; Hornykiewicz O
Neuroscience; 1991; 44(3):591-605. PubMed ID: 1754053
[TBL] [Abstract][Full Text] [Related]
16. Parkinson's disease without nigral degeneration: a pathological correlate of scans without evidence of dopaminergic deficit (SWEDD)?
Ling H; Kearney S; Yip HL; Silveira-Moriyama L; Revesz T; Holton JL; Strand C; Davey K; Mok KY; Polke JM; Lees AJ
J Neurol Neurosurg Psychiatry; 2016 Jun; 87(6):633-41. PubMed ID: 26209716
[TBL] [Abstract][Full Text] [Related]
17. Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss.
Brooks AI; Chadwick CA; Gelbard HA; Cory-Slechta DA; Federoff HJ
Brain Res; 1999 Mar; 823(1-2):1-10. PubMed ID: 10095006
[TBL] [Abstract][Full Text] [Related]
18. Magnetic Resonance Imaging Features of the Nigrostriatal System: Biomarkers of Parkinson's Disease Stages?
Hopes L; Grolez G; Moreau C; Lopes R; Ryckewaert G; Carrière N; Auger F; Laloux C; Petrault M; Devedjian JC; Bordet R; Defebvre L; Jissendi P; Delmaire C; Devos D
PLoS One; 2016; 11(4):e0147947. PubMed ID: 27035571
[TBL] [Abstract][Full Text] [Related]
19. Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders.
Tong J; Rathitharan G; Meyer JH; Furukawa Y; Ang LC; Boileau I; Guttman M; Hornykiewicz O; Kish SJ
Brain; 2017 Sep; 140(9):2460-2474. PubMed ID: 29050386
[TBL] [Abstract][Full Text] [Related]
20. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
